Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.2200413119 http://scihub22266oqcxt.onion/10.1073/pnas.2200413119 35576468!9173764!35576468     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2022 ; 119 (21): e2200413119 Nephropedia Template TP {{tp|p=35576468|t=2022. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies |pdf=|usr=}}{{35576468}} gab.com Text The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=35576468 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-alpha, IFN-omega, and/or IFN-beta are found in approximately 20% of deceased patients across age groups, and in approximately 1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-alpha2 or IFN-omega, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and >/=70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those >/=80 y old for autoantibodies neutralizing IFN-alpha2 or IFN-omega, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-alpha2 and IFN-omega. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death. Twit Text FOAVip The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=35576468 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35576468 #FOAvip English Wikipedia <ref>{{Cite pmid|35576468}}</ref> The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies #MMPMID35576468 Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martinez A; Yang R; Haljasmagi L; Migaud M; Sarekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garcon P; Riviere JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Sole-Violan J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Velez M; Arias AA; Lorenzo L; Boucherit S; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarstrom Q; Hammarstrom L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari FS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Erikstrup C; Condino-Neto A; Prando C; Bondarenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; Anderson MS; Boisson B; Beziat V; Zhang SY; Andreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Burdet C; Bouadma L; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodriguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Casanova JL; Abel L; Cobat A Proc Natl Acad Sci U S A 2022[May]; 119 (21): e2200413119 PMID35576468show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-alpha, IFN-omega, and/or IFN-beta are found in approximately 20% of deceased patients across age groups, and in approximately 1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-alpha2 or IFN-omega, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and >/=70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those >/=80 y old for autoantibodies neutralizing IFN-alpha2 or IFN-omega, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-alpha2 and IFN-omega. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death. |*Antibodies, Neutralizing/blood[MESH] |*Autoantibodies/blood[MESH] |*Autoimmunity[MESH] |*COVID-19/immunology/mortality[MESH] |*Interferon Type I/immunology[MESH] |*SARS-CoV-2[MESH] |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH]The risk of COVID-19 death is much greater and age dependent with type(epmc).pdf DeepDyve Pubget Overpricing